Free Trial
NASDAQ:PULM

Pulmatrix Q2 2023 Earnings Report

Pulmatrix logo
$6.41 +0.03 (+0.47%)
Closing price 05/5/2025 03:58 PM Eastern
Extended Trading
$6.22 -0.19 (-2.89%)
As of 05/5/2025 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmatrix EPS Results

Actual EPS
-$1.04
Consensus EPS
-$1.23
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
$1.84 million
Expected Revenue
$1.51 million
Beat/Miss
Beat by +$330.00 thousand
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Pulmatrix's Q1 2025 earnings is scheduled for Friday, May 9, 2025

Pulmatrix Earnings Headlines

Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM), a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

View Pulmatrix Profile

More Earnings Resources from MarketBeat